{"contentid": 487955, "importid": NaN, "name": "MANTA-RAy gives hope for future of filgotinib", "introduction": "Interim data from the MANTA-RAy and MANTA safety studies will help calm nerves at Belgian biotech Galapagos, with data pointing in the right direction for filgotinib.", "content": "<p>Interim data from the MANTA-RAy and MANTA safety studies will help calm nerves at Belgian biotech Galapagos (Euronext: GLPG), with data pointing in the right direction for filgotinib.</p>\n<p>The JAK-1 blocker - a class of treatment which has been beset with safety issues - was handed a Complete Response Letter (CRL) from the US regulator in 2020, delaying any possible approval there in rheumatoid arthritis.</p>\n<p>The therapy is approved and marketed in this indication in Europe, the UK, and Japan, as a second-line option. In these territories, it is sold under the brand Jyseleca.</p>\n<p>In the USA, the Food and Drug Administration has expressed worries about the potential impact on testicular health of the higher, more effective, 200mg dose.</p>\n<p>The interim analysis shows that, of the 240 people evaluated after 13 weeks of treatment, sperm concentration fell by at least half in eight out of 120 in the test group and 10 out of 120 in the placebo group.</p>\n<h2>Jyseleca progress</h2>\n<p>A positive sign for what is a key asset for Galapagos, the interim data boosted the firm&rsquo;s share price on Thursday, but investors will have to wait for more complete data - due later in the year - for a clearer picture.</p>\n<p>It is hard to overstate the importance of Jyseleca to the firm. As well as being central to a multi-billion dollar R&amp;D agreement with Gilead (Nasdaq: GILD), the therapy is a key test of the firm&rsquo;s technology and approach.</p>\n<p>While Gilead is continuing with the program in inflammatory bowel conditions, the firm has already returned rights in rheumatoid diseases, following last year&rsquo;s regulatory rebuff.</p>\n<p>Commenting on the latest interim data, Galapagos chief medical officer Walid Abi-Saab said: \"We are pleased the interim results reported today will be submitted to the relevant regulatory authorities.&rdquo;</p>\n<p>When the MANTA and MANTA-RAy trials are completed, the firms plan to submit the full results for publication in a peer-reviewed medical journal.</p>", "date": "2021-03-05 14:08:00", "meta_title": NaN, "meta_keywords": "data, interim, MANTA-RAy, filgotinib, Galapagos, safety, MANTA, future, hope, biotech, nerves, Belgian, calm, studies, pointing, direction, Jyseleca, firms", "meta_description": "Interim data from the MANTA-RAy and MANTA safety studies will help calm nerves at Belgian biotech Galapagos, with data pointing in the right direction for filgo", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-05 10:34:11", "updated": "2021-03-05 14:09:44", "access": NaN, "url": "https://www.thepharmaletter.com/article/manta-ray-gives-hope-for-future-of-filgotinib", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "galapagos_large.jpg", "image2id": "galapagos_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Immunologicals", "topic_tag": "Drug Trial, Focus On, Research, US FDA", "geography_tag": "Belgium, USA", "company_tag": "Galapagos, Gilead Sciences", "drug_tag": "filgotinib, Jyseleca", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-05 14:08:00"}